LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) — ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, to acquire all of the outstanding shares of ACELYRIN for $3.00 per share in cash, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of ACELYRIN’s development programs or intellectual property. On February 6, 2025, ACELYRIN announced an agreement to merge with Alumis Inc. (Nasdaq: ALMS) in an all-stock transaction. The transaction is expected to close in the second quarter of 2025,...

This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important information” at the end of this press release and in the offer document published on the transaction website (www.raredisease-offer.com). Shareholders in the United States should also refer to the section titled “Special notice to shareholders in the United States” at the end of this press release. Leiden,...

Deal Marks Expansion Outside of North America Creating a Platform for International Growth NEW YORK and LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) — Bishop Street Underwriters (“Bishop Street”), a RedBird Capital Partners portfolio company, today announced that it has completed its acquisition of Landmark Underwriting (“Landmark”), a specialty-focused managing general agent (“MGA”) based in London. This deal continues Bishop Street’s rapid expansion, growing its investment footprint outside of North America for the first time, and further strengthening the capabilities of its platform. Financial terms of the deal were not disclosed.  As a well-positioned high-growth MGA with an established panel of rated capacity partners, this deal brings Landmark’s specialized and dynamic team to the Bishop Street platform, in support of building...

Tarkett Participation, Tarkett’s controlling shareholder, announces its intention to file a public buy-out offer, followed by a squeeze-out, on the Tarkett shares it does not holdOffer at a price of 16 euros per share, representing a premium of 32.3% and 37.5% over respectively the volume-weighted average share price over the last 20 and 60 trading days Appointment of an ad hoc Committee comprising a majority of independent members of the Supervisory Board, and designation of Finexsi – Expert & Conseil Financier as independent expert Based on a recommendation of its ad hoc Committee, Tarkett’s Supervisory Board has favorably and unanimously welcomed the proposed public buy-out offer followed by a squeeze-outPARIS, FRANCE, February 20, 2025 – Tarkett Participation announces its intention to file in the...

NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) — NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (“THE CODE”). THIS ANNOUNCEMENT CONSTITUTES INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. For immediate release 20 February 2025 HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”) Further to the announcement on 2 January 2025 regarding the non-binding discussions for an all-share acquisition...

Majority stake acquisition strengthens BitFuFu’s operational scale and efficiency with low-cost power and enhanced hosting capacity Net electricity cost at this facility is very competitive at about $0.03 per kWh With the deployment of AntMiner S21 series miners, the average cash cost to mine one Bitcoin at this site is as low as $18,000, excluding depreciationSINGAPORE, Feb. 20, 2025 (GLOBE NEWSWIRE) — BitFuFu Inc. (“BitFuFu” or the “Company”) (NASDAQ: FUFU), a global leader in Bitcoin mining and comprehensive mining services, today announced that it has signed a definitive agreement and acquired a majority ownership in a 51-megawatt (MW) operational Bitcoin mining data center in Oklahoma. The transaction, priced at $400,000 per MW, is funded with cash from BitFuFu’s balance sheet and common stock. Strategic Benefits of the...

TORONTO, Feb. 20, 2025 (GLOBE NEWSWIRE) — Quisitive Technology Solutions, Inc. (“Quisitive” or the “Company”) (TSXV: QUIS; OTCQX: QUISF) is pleased to announce that two leading independent proxy advisory firms, including Institutional Shareholder Services Inc. (“ISS”), have recommended that holders (the “Shareholders”) of common shares of Quisitive (the “Shares”) vote “FOR” the resolution approving the proposed acquisition of Quisitive by an affiliate of funds managed by H.I.G. Capital, LLC pursuant to a plan of arrangement under the Business Corporations Act (British Columbia) (the “Arrangement”). The ISS report states that, among other things, “the offer represents a meaningful premium to the unaffected price, the special committee appears to have run a robust process…As such, support for the proposal is warranted.” The ISS report...

Founder & President Tom VanVeckhoven Joins UPSTACK as Partner NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) — UPSTACK, the leading full-service technology advisory firm, today announced the acquisition of Arkansas-based V3 Technology Inc., an IT advisory firm providing innovative technology strategies for midmarket businesses. As part of the deal, V3 Technology President Tom VanVeckhoven will join UPSTACK as a Partner. The V3 team, including Miles VanVeckhoven, V3’s Vice President of Sales and Operations, also will join UPSTACK. Founded in 2012, V3 Technology is a powerful group of telecom and IT veterans with more than 70 years of combined experience working with service providers to help customers maximize the benefits of their IT and telecom infrastructure while minimizing the use of their time and resources. “Tom,...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES (Note: All dollar amounts in this news release are expressed in U.S. dollars, except as otherwise noted). TORONTO, Feb. 20, 2025 (GLOBE NEWSWIRE) — Fairfax India Holdings Corporation (“Fairfax India” or the “Company”) (TSX: FIH.U) announces that, through its wholly-owned subsidiary, it has completed the acquisition of an additional 10% equity interest in Bangalore International Airport Limited (“BIAL”) from Siemens Project Ventures GmbH, part of Siemens Financial Services for, in aggregate, $255.0 million (the “Purchase Price”). As previously announced, the Purchase Price is payable in three installments, with the initial installment paid on closing of the transaction and the balance to be paid on August 31, 2025 and July 31, 2026. As a result...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ALLIANCE PHARMA PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...